Physician profile
Patrick E Evivie
NPI 1285612374
$12,622.72
in general payments reported to CMS, 2019-2025
44 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,736 · 2020: $1,397 · 2021: $2,054 · 2022: $2,071 · 2023: $1,784 · 2024: $1,568 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,344 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,343.87 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,265.48 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,523.79 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,082.42 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $852.70 | 2019-2025 | Jardiance |
| Pfizer INC. | $800.05 | 2019-2025 | |
| Amgen INC. | $727.96 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $665.27 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $546.24 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $535.01 | 2021-2025 | |
| Abbvie INC. | $495.01 | 2021-2025 | |
| Glaxosmithkline, LLC. | $402.61 | 2019-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $265.99 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $225.12 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $225.10 | 2019-2021 | |
| Gilead Sciences, INC. | $216.03 | 2019 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Evivie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.